Novo Nordisk (NVO) raised its outlook for the year, after strong early demand for its oral Wegovy pill helped revive momentum in its obesity business. Excluding the 340B provision reversal, the Danish ...

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

This new high dose Wegovy data could help support Novo Nordisk in its bid to claw back market share taken by Eli Lilly in the obesity space.

These drugs fall into a class known as GLP-1s, mimicking a natural hormone that helps regulate blood sugar, slows how quickly food leaves the stomach, and signals the brain that you’re full. “I would ...

Weight-loss injections, such as Wegovy and Mounjaro, have transformed how we treat obesity. Around 1.6 million adults in ...

Oral option success: The ATTAIN-MAINTAIN trial showed patients switching to orforglipron after injectables kept most of their weight off compared with those stopping therapy. High-dose impact: Novo ...

Early signs from the launch of Novo Nordisk's Wegovy pill and Eli Lilly & Co.'s Foundayo are making investors rethink the opportunity for GLP-1 pills.

The Wegovy pill launched Monday, and the starting dose is now available at pharmacies around the country with higher doses arriving by the end of the week. The Food and Drug Administration approved ...

Novo reported 1.3 million prescriptions for its weight-loss pill, which is now available in the U.S., in the first quarter of ...

Novo Nordisk (CPSE:NOVO B) shocked the market with first quarter 2026 results, as its new oral Wegovy weight loss pill quickly surpassed 2 million US prescriptions and prompted a higher full year ...

COPENHAGEN, Denmark – Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering doses of 1.5 milligrams and 4 mg at $149 per month for self-paying ...